Subacute cutaneous lupus erythematosus

6 trials 1 recruiting MedDRA PT
6 Registered trials
1 Recruiting
3 Unique sponsors
3 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
JAK inhibitor 1 substance
Unknown / small molecule 1 substance
Phase III: 3 Phase II/III: 1 Phase II: 1 Phase I (Other): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

3 trials
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-504863-17-00 11 countries 2024 n=202
    Recruiting
  • Merck Healthcare KGaA Commercial
    ENPATORAN HEMIHYDRATE
    2025-523871-44-00 10 countries n=54
    Pending
  • Merck Healthcare KGaA Commercial
    ENPATORAN HEMIHYDRATE
    2025-524855-30-00 10 countries n=57
    Pending

Phase II/III

1 trial
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-505634-94-00 11 countries 2023 n=217
    Ended

Phase II

1 trial
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    DEUCRAVACITINIB
    2023-504161-22-00 3 countries 2021 n=36
    Ended

Phase I (Other)

1 trial
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2022-503009-39-00 6 countries 2024 n=37
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Biogen Idec Research Limited Commercial 2 Phase II/III, Phase III 1
Bristol-Myers Squibb Services Unlimited Company Commercial 2 Phase I (Other), Phase II 0
Merck Healthcare KGaA Commercial 2 Phase III 0
New trials by year
2021
1
2023
1
2024
2
← All indication landscapes